MLTX(MLTX)
MLTX
ANALYST COVERAGE17 analysts
BUY
▲ +66.1%upside to target
L $10.00
Med $29.50consensus
H $45.00Key MetricsTTM
Market Cap$1.31B
Revenue TTM$0.00
Net Income TTM-$257.08M
Free Cash Flow-$224.15M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-85.6%
Return on Assets-64.2%
Debt / Equity0.40
Current Ratio8.60
EPS TTM$-3.61
PRICE
Prev Close
17.05
Open
16.83
Day Range16.75 – 17.85
16.75
17.85
52W Range5.95 – 62.75
5.95
62.75
21% of range
VOLUME & SIZE
Avg Volume
1.1M
FUNDAMENTALS
P/E Ratio
-4.6x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
42
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
MLTX News
About
moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Nuala BrennanChief Clinical Development Officer
Jorge Santos da SilvaCo-Founder, Interim Chair of the Board & CEO
Kristian ReichCo-Founder & Chief Scientific Officer
Joana CortezAssociate Vice-President of Legal & Compliance
Luciana MarquesAssociate Vice-President of HR, People and Culture
Matthias BodenstedtChief Financial Officer
Nicolas MosimannGeneral Counsel
Oliver DaltropChief Technical Officer
Carla BretesDirector of Investor Relations & External Communications
Roman Akbar-HaaseChief of Staff to the Executive Board
Tino AnthamattenVice President of Marketing, Market Access & Pricing
Wulf BoecherChief Medical Officer